Ono Teams Separately With Onyx And Concordia To Continue Its In-Licensing Oncology Expansion
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Ono Pharmaceutical has signed separate licensing agreements with Onyx and Concordia for oncology products, deals which the company said has caused it to lower its yearly forecast due to higher than expected in-licensing payments